Shamburg News · 8-K filed Nov 16, 2026, 7:05 AM EST
Xtant Medical Reports Q3 2026 Results and Announces Board-Led Strategic Review Process
XTNT · Xtant Medical Holdings, Inc.
- Earnings
- Other event
- Materiality: high
Xtant Medical Holdings reported third quarter 2026 total revenue of $24.3 million, down from $33.3 million a year earlier and up 5% from $23.0 million in the second quarter, with a net loss of $3.6 million, or $0.03 per share. Adjusted EBITDA was a loss of $1.5 million, compared with adjusted EBITDA of $4.5 million for the prior-year quarter. The company no longer expects to achieve its previously issued full-year 2026 guidance and is not providing revised guidance, and its Board announced a strategic review process with no set timetable.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001493152-26-051996.
Written from the filing by Shamburg Markets. Figures are as reported by the company.